Abstract
Several recently published clinical trials have shown tofacitinib to be effective in the treatment of autoimmune diseases. This drug is commonly prescribed either in a 5-mg or in a10-mg dosage twice daily. In this review, we aimed to systematically compare the adverse drug events which were observed with 5 mg versus 10 mg tofacitinib for the treatment of autoimmune diseases. MEDLINE, EMBASE, the Cochrane library, and www.ClinicalTrials.gov were searched (from March to April 2018) for suitable English publications (published before April 2018). The inclusion criteria were as follows: randomized controlled trials, autoimmune disorders (rheumatic arthritis, psoriatic arthritis, moderate to severe psoriasis, and ankylosing spondylitis), and comparison of adverse drug events associated with 5 mg versus 10 mg tofacitinib. This study had follow-up time periods of 3 months and ≥ 6 months. Statistical analysis was carried out by RevMan 5.3 whereby risk ratios (RRs) and 95% confidence intervals (CIs) were generated. A total number of 4287 participants were included (2144 versus 2143 participants who received 5 mg and 10 mg tofacitinib twice daily respectively). The results showed that at 3 months, similar risks of adverse drug events, serious adverse events, and adverse events leading to drug discontinuation were observed with 5 mg versus 10 mg tofacitinib (RR 1.04, 95% CI 0.98–1.10; P = 0.17, I2 = 0%; RR 1.06, 95% CI 0.77–1.48; P = 0.71, I2 = 0%; and RR 1.06, 95% CI 0.78–1.43; P = 0.73, I2 = 32%, respectively). The other outcomes including serious infection events, adjudicated herpes zoster infection, adjudicated opportunistic infection, mild and severe neutropenia, malignancies, and adjudicated major adverse cardiovascular events were also similarly manifested. However, a decreased level of hemoglobin significantly favored 5 mg tofacitinib (RR 1.75, 95% CI 1.19–2.58; P = 0.005, I2 = 49%). Even at a follow-up time period of ≥ 6 months, adverse drug events, serious adverse events, adverse drug events leading to drug discontinuation, and serious infection were still similarly observed. According to this current review, both dosages of tofacitinib were safe to use. Even if similar adverse drug events were observed with 5 mg versus 10 mg tofacitinib twice daily for the treatment of autoimmune disorders, anemia was more prominent with 10 mg tofacitinib at a 3 month follow-up. Nevertheless, future studies based on a larger population size with longer follow-up time periods should further be considered.
Similar content being viewed by others
References
O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A (2013) Janus kinase Inhibitors in autoimmune diseases. Ann Rheum Dis 72(0 2):ii111–ii115
Steve C (2017) Janus kinase inhibitors for autoimmune disorders. Therapy review
Rivellese F, Lobasso A, Barbieri L, Liccardo B, De Paulis A, Rossi FW (2018) Novel therapeutic approaches in rheumatoid arthritis: role of Janus kinases inhibitors. Curr Med Chem 25. https://doi.org/10.2174/0929867325666180209145243
Yamaoka K (2016) Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 32:29–33
Louder A, Singh A, Saverno K et al (2016) Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits 9:84–93
Sivaraman P, Cohen SB (2017) Malignancy and Janus kinase inhibition. Rheum Dis Clin N Am 43(1):79–93
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS, ORAL Solo Investigators (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367(6):495–507
Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377(16):1525–1536
Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537–1550
Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S (2016) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-termextension study. J Am Acad Dermatol 74(5):841–850
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B, Standard Investigators ORAL (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367(6):508–519
Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C, ORAL Step investigators (2013) To facitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoidarthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3trial. Lancet 381(9865):451–460
Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patientswith active rheumatoid arthritis: a randomized trial. Ann Intern Med 159(4):253–261
Higgins JP, et al. (2008) Assessing risk of bias in included studies, in Cochrane handbook for systematic reviews of interventions. Wiley 187–241
van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, Li D, Menon S, Kanik KS (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76(8):1340–1347
Kawalec P, Mikrut A, Wiśniewska N, Pilc A (2013) The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 32(10):1415–1424
Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumabmonotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying anti rheumatic drugs. Arthritis Rheum 64(3):617–629
Ghoreschi K, Gadina M (2014) Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp Dermatol 23(1):7–11
Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K (2013) A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 169(1):137–145
Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386
Fleischmann R, Huizinga T, Kavanaugh AF et al (2016) Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2:e000262
Dhillon S (2017) Tofacitinib: a review in rheumatoid arthritis. Drugs 77(18):1987–2001
Wallenstein GV, Kanik KS, Wilkinson B, Cohen S, Cutolo M, Fleischmann RM, Genovese MC, Gomez Reino J, Gruben D, Kremer J, Krishnaswami S, Lee EB, Pascual-Ramos V, Strand V, Zwillich SH (2016) Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two phase 2 randomised controlled trials. Clin Exp Rheumatol 34(3):430–442
Lundquist LM, Cole SW, Sikes ML (2014) Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop 5(4):504–511
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76(7):1253–1262
Machado MAÁ, Moura CS, Guerra SF, Curtis JR, Abrahamowicz M, Bernatsky S (2018) Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther 20(1):60
Schulze-Koops H, Strand V, Nduaka C, DeMasi R, Wallenstein G, Kwok K, Wang L (2017) Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatology (Oxford) 56(1):46–57
Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60:1895–1905
Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 63:1150–1158
Ni H, Moe S, Myint KT, Htet A (2013) Oral Janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib. ISRN Rheumatol 2013:357904
Gadina M (2013) Janus kinases: an ideal target for the treatment of autoimmune diseases. J Investig Dermatol Symp Proc 16(1):S70–S72
Acknowledgements
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Authors’ information
Dr. Feng Huang (M.D) is the first author.
Funding
No external funding was used in the preparation of this manuscript. This research was supported by the National Natural Science Foundation of China (No. 81560046, 81760057) and Guangxi Natural Science Foundation (No. 2016GXNSFAA380002).
Author information
Authors and Affiliations
Contributions
FH and ZL were responsible for the conception and design, acquisition of data, analysis and interpretation of data, and drafting the initial manuscript and revising it critically for important intellectual content. FH wrote and approved the final manuscript.
Corresponding author
Ethics declarations
Disclosures
None.
Rights and permissions
About this article
Cite this article
Huang, F., Luo, Zc. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol 38, 523–534 (2019). https://doi.org/10.1007/s10067-018-4299-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-018-4299-4